The use of massively parallel sequencing of maternal cfDNA for non-invasive prenatal testing (NIPT) of aneuploidy is widely available. Recently, the scope of testing has increased to include selected subchromosomal abnormalities,

With almost 17 million live births in 2014, China is already one of the largest potential markets for prenatal diagnostics, including noninvasive testing of fetal DNA in the mother's blood to detect fetal chromosomal defects.

Among the in vitro diagnostic (IVD) testing trends in 2015 were smaller molecular instruments, better information technology (IT) systems, and progress on use of sequencing in clinical medicine.

As a new arose field, mobile health care has been attracted by public, from giant BAT to various of capitals they all want to put their feet into it.

Wanda Group and IHG(International Hospitals Group Limited) recently have made a strategic cooperation agreement in Beijing. Wanda will invest a total of 15 billion yuan in Shanghai,

The 34th Annual JP Morgan Healthcare Conference began here Monday with several life science research tools and diagnostic firms making presentations to investors and other attendees.

Courtagen Life Sciences reported today that it has completed the comprehensive Clinical Laboratory Evaluation Program and has received its clinical laboratory permit form the state of New York.

Foundation Medicine announced today that it has formed a three-way collaboration with Horizon Healthcare Services and Clinical Outcomes Tracking

Illumina and China's Novogene today announced an agreement to jointly develop next-generation sequencing applications for reproductive health and oncology.

As a new type of genetic testing technology, Gene Sequencing analyzes and tests complete gene sequencing through blood or ptysma which can forecast the possibility of personal diseases and different kinds of behaviora..

The American Heart Association (AHA), Verily (formerly Google Life Sciences) and AstraZeneca ($AZN) have chipped in a total of $75 million over 5 years to support "one brave idea from a visionary leader" to cure coronary heart disease.

Thermo Fisher Scientific said after the close of the market Friday that it is acquiring Affymetrix for approximately $1.3 billion.

Lepu Medical Technologies announced recently to prepare the big issue of acquisition with estimated amount of ￥650 million to ￥1.2 billion and the acquisition target embraced cardiovascular drug enterprises and hospitals.

Now 2016 has come, but for Theranos, which was just revealed a serious fraud technically in 2015, the new year doesn’t seem good.

NeoGenomics said today it has agreed to acquire Clarient and its wholly-owned subsidiary Clarient Diagnostic Services from GE Healthcare.